Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/3/26 16:24 | 4/1/26 | TECX | Health | BioPrd | Biological Products, (No Diag | Ruddy Marcella K. | MA | O | Chief Me | 2 | S | -331 | 30.10 | 0 | -11 | 70 | D | |||||||||||||||
3/9/26 18:12 | 3/6/26 | TECX | Health | BioPrd | Biological Products, (No Diag | McNamara Peter | MA | O | Chief Sc | 3 | M.dm | 276 | 22.46 | 0 | 12 | 26 | 59 | D | ||||||||||||||
3/9/26 18:12 | 3/6/26 | TECX | Health | BioPrd | Biological Products, (No Diag | McNamara Peter | MA | O | Chief Sc | 3 | S.dm | -276 | 22.46 | 0 | -12 | 59 | D | |||||||||||||||
3/5/26 16:30 | 2/11/26 | TECX | Health | BioPrd | Biological Products, (No Diag | Reicin Alise | MA | DO | CEO | 2 | P | 106 | 21.10 | 0 | 5 | 1 | 362 | I | ||||||||||||||
2/12/26 16:15 | 2/10/26 | TECX | Health | BioPrd | Biological Products, (No Diag | Schwabish Marc | MA | O | Chief Bu | 1 | M.d | 11 | 2.38 | 0 | 5 | 21 | 26 | D | ||||||||||||||
2/11/26 17:32 | 2/10/26 | TECX | Health | BioPrd | Biological Products, (No Diag | Lochner Daniel | MA | O | CFO | 1 | P | 130 | 21.61 | 0 | 6 | 23 | 32 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |